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Digital health interventions for children with ADHD
Attention deficit hyperactivity disorder (ADHD) is a 
childhood-onset disorder characterised by a persistent 
pattern of symptoms of inappropriate and impaired 
inattention, hyperactivity, or impulsivity, with difficulties 
often continuing into adulthood.1 It is estimated to affect 
37·1 million children and young people (aged ≤20 years) 
worldwide.2  Although multiple ADHD treatments are 
available and widely used (eg, evidence-based behaviour 
therapy, medications, or a combination of both),3,4 their 
effectiveness has been questioned because they might 
not fully address the needs of many children with ADHD. 
Barriers to evidence-based treatment for ADHD include 
misconceptions and stigma, time, and complexity of 
interventions, among others.5 Digital health interventions, 
such as those delivered via mobile-based, tablet-based, 
and web-based platforms, offer diverse possibilities of 
treatment to address many of the barriers because these 
interventions can be accessed from everywhere, might 
support integration across multiple settings (eg, home, 
education, and health services), and can empower the 
individuals (and families) to take care of themselves. The 
evidence base for digital mental health interventions is 
rapidly accumulating.6,7 For example, a 2017 overview 
with an updated systematic review of randomised trials7 
identified 21 reviews and 30 randomised controlled 
trials of digital health interventions for children and 
young people with mental health problems. Of these, 
10 (33%) trials in 853 participants evaluated digital 
health interventions (including video game programs 
or computer programs) aimed at improving ADHD 
outcomes. The review concluded that the effects of digital 
mental health interventions in managing children with 
ADHD were uncertain.7
In The Lancet Digital Health, Scott Kollins and colleagues8 
sought to provide evidence for the effectiveness of a 
digital health intervention on attentional functioning 
and symptoms in children diagnosed with ADHD. The 
authors did a randomised, double-blind, parallel-group, 
controlled trial, comprising 348 children with ADHD 
(aged 8–12 years). Participants were randomised to a 
video game-like digital health intervention accessed 
via a tablet-platform (n=180) or a control intervention 
(n=168). The primary outcome was the mean change 
in the Attention Performance Index (API), an overall 
composite score from the Test of Variables of Attention 
(TOVA). Secondary outcomes included mean changes in 
non-composite scores on TOVA, spatial working memory 
(ie, Cambridge Neuropsychological Test Automated 
Battery), clinician-rated ADHD symptoms (ie, ADHD-
Rating Scale [ADHD-RS] subscale and total scale), 
executive function (ie, parent-completed Behaviour 
Rating Inventory of Executive Function subscale), 
impairment (ie, Impairment Rating Scale [IRS]), and 
global functioning (ie, Clinical Global Impression-
Improvement [CGI-I] score). Moreover, treatment 
response (ie, proportion of responders at appropriate 
cutoff points on the same rating scales) and safety (ie, 
any adverse event) were examined. Overall, the authors 
found that a video game-like digital health intervention 
resulted in a small but significant effect in improving 
attention after 4 weeks of treatment (mean change [SD] 
from baseline on the composite score from the TOVA API 
was 0·93 [3·15] in the intervention group and 0·03 [3·16] 
in the control group, adjusted p value 0·0060). However, 
an effect was not observed in any of the prespecified 
secondary outcomes, which included some of the most 
prominent symptom rating scales. As acknowledged by 
the authors, there were no significant between-group 
differences in secondary measures (eg, ADHD-RS, CGI-I 
score, IRS, working memory). Thus, the study was unable 
to address a major challenge in treatment of children 
with ADHD, which ultimately should target not only the 
severity of impairment but also functional outcomes 
(school performance–social functioning) at that age.
The study has several strengths. The research design, 
which incorporated a randomisation schedule to 
intervention allocation, masking (of parents, children, 
and investigators), and its size, which was considerably 
larger than any of the previous studies in digital mental 
health.7 The use of standardised measurement tools, 
which were applied in two different ways (ie, difference 
between baseline and post-treatment score, and the 
proportion of responders as an estimate of clinical 
relevance). The study is also associated with certain 
limitations. 4 weeks of treatment exposure (with 
25-min daily sessions, approximately) is relatively 
short. Some difficulties were observed in completing 
intention-to-treat analysis because of invalid tests or 
missing data. Thus, the authors excluded participants 
after the random assignment in their main analyses, 
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which is referred to as modified intention-to-treat.9 
The study also excluded patients with comorbidities 
and patients receiving concomitant treatments, as 
have previous studies, and thus there are no data on 
the efficacy (and safety profile) of the digital health 
intervention in these populations.
However, Kollins and colleagues did give a preliminary 
indication of the efficacy of a video game-like 
digital health intervention to improve inattention 
in a paediatric population with ADHD. What are the 
implications of these findings for clinical practice? 
Specifically, how confident should we about the benefits 
of this digital health intervention for ADHD, and what 
do the data tell us about the use of the intervention 
in the target population? The results of Kollins and 
colleagues’ study are interesting and highlight the way 
for further development of digital health interventions 
for children with ADHD. Some might argue that efficacy 
of digital health interventions should be shown on 
patients with all subtypes of ADHD, and analyses of 
effects on subtypes (eg, predominantly inattentive 
ADHD) might be considered secondary. Because of 
the chronic course of ADHD, in addition to short-term 
trials, long-term efficacy should be established in future 
studies.10 Thus, further research is needed to examine 
ways of sustaining treatment effects over the long-
term, in the broader population of children with ADHD 
including those who have comorbidities and receive 
evidence-based therapies.
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